Effect of Rebamipide (Mucosta(R)) in Eradication of Helicobacter pylori / 대한소화기내시경학회지

ABSTRACT

BAKGROUND/AIMS: Eradication of Helicobacter pylori infection is highly efficacious in preventing the recurrence of peptic ulcer. Rebamipide (Mucosta(R)) is known to have the ability to inhibit neutrophil activity, to reduce the production of inflammatory cytokines, to scavenge oxygen radical, and to stimulate prostaglandin production. This study was designed to evaluate the effect of rebamipide on the eradication of H. pylori, and decrease of the infilatration of inflammatory cells. METHODS: Eighty two patients with gastric or duodenal ulcers with H. pylori infection were allocated to two treatment groups. The patients were treated either with omeprazole 40 mg, clarithromycin 1.0 g, amoxicillin 2.0 g, rebamipide 300 mg (OCAR group) or omeprazole 40 mg, clarithromycin 1.0 g, amoxicillin 2.0 g (OCA group) for two weeks. RESULTS: H. pylori was eradicated 56 out of 62 patients (90%) in OCAR group and 16 out of 20 patients (80%) in OCA group. The infiltration of inflammatory cells decreased in both treatment groups. No significant side effects had been noticed. CONCLUSIONS: The results of the present study suggest that rebamipide may be useful to decrease gastric mucosal inflammation in peptic ulcer disease. However, further detailed study will be reqiured to determine the potentially beneficial effect whether rebamipide can prevent the recurrence of peptic ulcer diseases with H. pylori infection.